Are there better drugs for adult epilepsy than lamotrigine

The short version: for adults, no drug has been shown to beat lamotrigine across the board. Valproate wins on raw seizure response in generalized epilepsy, but its side-effect burden is higher.

For adults with idiopathic generalized epilepsy, valproate had the highest response rate, about 71 in 100 versus 40 in 100 for lamotrigine, and levetiracetam about 48 in 100 [1]. But valproate also caused side effects that forced a treatment change in about 24 in 100, versus 10 in 100 for lamotrigine [1]. Only about 19 in 100 of the whole group got seizure freedom with acceptable side effects on the first drug tried [1]. That is the real number to sit with.

In the elderly with newly diagnosed epilepsy, no monotherapy clearly won on seizure freedom, and lamotrigine, levetiracetam and lacosamide ranked highest for control while carbamazepine had worse tolerability [2]. For focal epilepsy, lamotrigine and oxcarbazepine were noninferior to carbamazepine, and levetiracetam matched slow-release carbamazepine on remission [3].

The honest gap: these are mostly retrospective or observational cohorts, not head-to-head trials with long follow-up. None compares any drug to an untreated group over years. Lamotrigine's edge is tolerability, not potency [1][2].

My call: valproate is more effective but harder to tolerate in adults with generalized epilepsy; lamotrigine remains a reasonable first choice where side effects matter most. Confidence: moderate for the response gap, low for long-term superiority.